Families Hit Back At GSK'S Zofran Fraud Dismissal Bid

Law360, New York (January 4, 2017, 2:14 PM EST) -- Plaintiffs in a multidistrict litigation against GlaxoSmithKline PLC told a Massachusetts federal court Tuesday that they adequately set out off-label fraud claims in master complaints linking the anti-nausea drug Zofran to birth defects.

Although the master complaints lack granular detail about the alleged fraud, they lay out exactly what is needed at this stage in the MDL, which involves hundreds of people claiming their babies were injured or died as a result of prenatal exposure to the drug, according to the parents' opposition brief.

The filing...
To view the full article, register now.